BetterLife Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD

BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!

Read more